The Effect of Ligand Lipophilicity on the Nanoparticle Encapsulation of Pt(IV) Prodrugs
- 16 July 2013
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 52 (17) , 9915-9920
Abstract
In an effort to expand the therapeutic range of platinum anticancer agents, several new approaches to platinum-based therapy, including nanodelivery, are under active investigation. To better understand the effect of ligand lipophilicity on the encapsulation of Pt(IV) prodrugs within polymer nanoparticles, the series of compounds cis,cis,trans-[Pt(NH3)2Cl2L2] was prepared, where L = acetate, propanoate, butanoate, pentanoate, hexanoate, heptanoate, octanoate, nonanoate, and decanoate. The lipophilicities of these compounds, assessed by reversed-phase HPLC, correlate with the octanol/water partition coefficients of their respective free carboxylic acid ligands, which in turn affect the degree of encapsulation of the Pt(IV) complex within the hydrophobic core of poly(lactic-co-glycolic acid)-block-poly(ethylene glycol) (PLGA-PEG-COOH) nanoparticles. The most lipophilic compound investigated, cis,cis,trans-[Pt(NH3)2Cl2(O2C(CH2)8CH3)2], displayed the best encapsulation. This compound was therefore selected to evaluate the effect of increased platinum concentration on encapsulation. As the platinum concentration was increased, there was an initial increase in encapsulation followed by a decrease due to macroscopic precipitation. Maximal loading occurred when the platinum complex was present at a 40% w/w ratio with respect to polymer during the nanoprecipitation step. Particles formed under these optimal conditions had diameters of approximately 50 nm, as determined by transmission electron microscopy.Keywords
This publication has 24 references indexed in Scilit:
- Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivoProceedings of the National Academy of Sciences, 2011
- Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapyProceedings of the National Academy of Sciences, 2010
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Polyvalent Oligonucleotide Gold Nanoparticle Conjugates as Delivery Vehicles for Platinum(IV) WarheadsJournal of the American Chemical Society, 2009
- Impact of Nanotechnology on Drug DeliveryACS Nano, 2009
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- Targeted Single-Wall Carbon Nanotube-Mediated Pt(IV) Prodrug Delivery Using Folate as a Homing DeviceJournal of the American Chemical Society, 2008
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Soluble Single-Walled Carbon Nanotubes as Longboat Delivery Systems for Platinum(IV) Anticancer Drug DesignJournal of the American Chemical Society, 2007
- Platinum Compounds: a New Class of Potent Antitumour AgentsNature, 1969